Abstract: Disclosed are methods of isolating paired T cell receptor (TCR) alpha and beta chain sequences, or an antigen-binding portion thereof. Also disclosed are methods of automatically identifying the TCR alpha and beta chain V segment sequences and CDR3 sequences of a TCR having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Methods of preparing a population of cells that express paired TCR alpha and beta chain sequences, or an antigen-binding portion thereof, are also disclosed. Isolated pairs of TCR alpha and beta chain sequences and isolated populations of cells prepared by the methods are also disclosed.

Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide an updated insulin-to-carbohydrate ratio and an updated total daily insulin. The described processes may be used for periodic updating of the insulin-to-carbohydrate ratio and the total daily insulin. The insulin-to-carbohydrate ratio and/or the total may be used in the calculation of new doses of insulin that a drug delivery device may be commanded to deliver to a user.

Abstract: A pulsed magnetic particle imaging system includes a magnetic field generating system that includes at least one magnet, the magnetic field generating system providing a spatially structured magnetic field within an observation region of the magnetic particle imaging system such that the spatially structured magnetic field will have a field-free region (FFR) for an object under observation having a magnetic nanoparticle tracer distribution therein. The pulsed magnetic particle imaging system also includes a pulsed excitation system arranged proximate the observation region, the pulsed excitation system includes an electromagnet and a pulse sequence generator electrically connected to the electromagnet to provide an excitation waveform to the electromagnet, wherein the electromagnet when provided with the excitation waveform generates an excitation magnetic field within the observation region to induce an excitation signal therefrom by at least one of shifting a location or condition of the FFR.

Abstract: A magnesium zinc oxide (MZO) nanostructure modified quartz crystal microbalance (MZOnano-QCM) takes advantage of the unique sensing ability and biocompatibility of MZO-based nanostructures, and combines them with the dynamic impedance spectrum capability of the bulk acoustic wave (BAW) devices including QCM, to form a real-time, noninvasive and label-free cell monitoring biosensor, specifically detecting the susceptibility and resistance of bacterial and fungal strains and cancer cells to various antibiotic and antifungal drugs and anticancer drugs, respectively.

Abstract: Certain embodiments of the invention provide a method of detecting the presence of a biomarker associated with resistance to an mTOR kinase inhibitor in a subject, comprising determining the presence of the biomarker in a physiological sample from the subject, wherein the sample comprises a nucleic acid.

Abstract: A magnesium zinc oxide (MZO) nanostructure modified quartz crystal microbalance (MZOnano-QCM) takes advantage of the unique sensing ability and biocompatibility of MZO-based nanostructures, and combines them with the dynamic impedance spectrum capability of the bulk acoustic wave (BAW) devices including QCM, to form a real-time, noninvasive and label-free cell monitoring biosensor, specifically detecting the susceptibility and resistance of bacterial and fungal strains and cancer cells to various antibiotic and antifungal drugs and anticancer drugs, respectively.

Abstract: Certain embodiments of the invention provide a method of detecting the presence of a biomarker associated with resistance to an mTOR kinase inhibitor in a subject, comprising determining the presence of the biomarker in a physiological sample from the subject, wherein the sample comprises a nucleic acid.

Abstract: The present invention relates generally to molecular mechanisms of mTOR-related human diseases. More specifically, the invention relates to two novel related polypeptides, the ER-localization sequence (ELS) and Golgi-localization sequence (GLS) along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.